Mucosal Melanoma: Epidemiology, Biology and Treatment (Q38646125)

5 September 2017

Mucosal Melanoma: Epidemiology, Biology and Treatment (English)

1 reference

5 September 2017

1 reference

1 reference

Kristen R Spencer

1

1 reference

PubMed ID

26601869

5 September 2017

Janice M Mehnert

series ordinal

2

1 reference

5 September 2017

1 January 2016

1 reference

Cancer Treatment and Research

5 September 2017

1 reference

5 September 2017

167

1 reference

5 September 2017

295-320

1 reference

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma

5 September 2017

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Malignant melanoma of the skin of the head and neck. An analysis of 405 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Biochemotherapy in patients with advanced head and neck mucosal melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

KIT gene mutations and copy number in melanoma subtypes

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Primary malignant melanoma of the vagina: a clinicopathological analysis of 10 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Primary anorectal melanoma: an update

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

KIT as a therapeutic target in metastatic melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Mucosal melanoma: a clinically and biologically unique disease entity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Somatic activation of KIT in distinct subtypes of melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Malignant melanoma of the mucous membranes: a review of 119 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Primary malignant melanoma of the vagina

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Radical radiotherapy for 28 cases of mucosal melanoma in the nasal cavity and sinuses

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Radiotherapy for mucosal melanomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Major response to imatinib mesylate in KIT-mutated melanoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Extracutaneous malignant melanomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Outcomes in patients with mucosal melanomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Sphincter-sparing local excision and hypofractionated radiation therapy for anorectal melanoma: a 20-year experience.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Noncutaneous malignant melanoma: a prognostic model from a retrospective multicenter study

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Biochemotherapy in patients with metastatic anorectal mucosal melanoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Treatment approach and outcomes of vaginal melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Management of vulvar and vaginal melanomas: current and future strategies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Head and neck mucosal melanoma: a review

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Cancer immunotherapy comes of age

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Mucosal melanoma of the nose and paranasal sinuses, a contemporary experience from the M. D. Anderson Cancer Center.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Ipilimumab in patients with melanoma and brain metastases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Primary malignant melanoma of the mucous membranes

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

31 March 2020

Primary mucosal melanoma

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Mucosal melanoma of the head and neck

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Mucosal melanoma: pathogenesis, clinical behavior, and management

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Ipilimumab for patients with advanced mucosal melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Improved overall survival in melanoma with combined dabrafenib and trametinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Nivolumab in previously untreated melanoma without BRAF mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Mucosal melanomas: a case-based review of the literature

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Treatment of locally recurrent mucosal melanoma with topical imiquimod

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Noncutaneous melanoma have distinct features from each other and cutaneous melanoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years later

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Nivolumab plus ipilimumab in advanced melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_13

10.1007/978-3-319-22539-5_13

31 March 2020

Identifiers

DOI

1 reference

5 September 2017

1 reference

PubMed ID

26601869